Treatment with combined dabrafenib and trametinib in BRAF(V600E)-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation

Here, we report the case of a patient, diagnosed with BRAF(V600E)-mutated metastatic malignant melanoma M1a, who achieved a complete metabolic response after 7 months of treatment with the combination of dabrafenib and trametinib. After 31 months, the treatment was interrupted for patient’s decision...

Descripción completa

Detalles Bibliográficos
Autores principales: Brugnara, Sonia, Sicher, Mariacristina, Bonandini, Elena Maria, Donner, Davide, Chierichetti, Franca, Barbareschi, Mattia, Girardelli, Carlo Renè, Caffo, Orazio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819728/
https://www.ncbi.nlm.nih.gov/pubmed/29483930
http://dx.doi.org/10.7573/dic.212515
Descripción
Sumario:Here, we report the case of a patient, diagnosed with BRAF(V600E)-mutated metastatic malignant melanoma M1a, who achieved a complete metabolic response after 7 months of treatment with the combination of dabrafenib and trametinib. After 31 months, the treatment was interrupted for patient’s decision. To date October 2017, 18 months after the interruption of the treatment with the combination of dabrafenib and trametinib, follow-up Positron Emission Tomography (PET) scans are still documenting complete metabolic response.

Ejemplares similares